Table 2.
Trabectedin plus PLD exposure
| Trabectedin plus PLD treatment delivery | Evaluable patients (n = 77); n (%) | |
|---|---|---|
| Time on treatment (months) | Median (range) | 4.2 (0.7–18.6) |
| Cycles per patient from the study enrollment | Median (range) | 6.0 (1–21) |
| 1 cycle | 8 (10.4) | |
| 2 cycles | 14 (18.2) | |
| 3 cycles | 5 (6.5) | |
| 4 cycles | 6 (7.8) | |
| 5 cycles | 5 (6.5) | |
| 6 cycles | 21 (27.3) | |
| ≥ 7 cycles | 18 (23.4) | |
| Cycle duration (days)a | Median (range) | 21.0 (15.0–95.0) |
| Cumulative dose (mg/m2)b | Median (range); trabectedin/PLD | 5.4 (0.83–23.3)/141.7 (23.0–627.0) |
| Dose intensity (mg/m2/week) | Median (range); trabectedin/PLD | 0.3 (0.2–0.5)/7.9 (2.9–10.2) |
| Relative dose intensity (%) | Median (range); trabectedin/PLD | 81.4 (53.5–125.2)/79.3 (29.3–101.7) |
| Types of treatment | Outpatients | 68 (88.3) |
| Inpatients | 2 (2.6) | |
| Both | 7 (9.1) | |
Data shown are numbers and percentage of patients or median and range values with available data
aDuration of last cycle was set to 3 weeks. In all other cases, time between administrations was used
bAdministered dose divided by body surface area (BSA)